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small myocardial infarcts were observed in the heart. Treatment with r-RGD-Hiru- 
din,(lmg/kg and 5 q/kg, n=lZ)significantly reduced the area and number of minor myo- 
cardial infarction(pc0.01 conpared with control). CONCLUSIONS: We present a new 
model of minor myocardial infarction in rats in which the small coronary arteries are 
occluded by microthrombi. This model is useful to investigate the pathophysiology and 
treatment of minor myocardial infarction which is ccmmcn in interventional treatment. R- 
RGD-Hirudin may be beneficial in the treatment of minor myocardial infarction induced 
by PTCA. 
1024-116 Implantation of Bone Marrow Stromal Cells Into 
lschamic Myocardium Prevents Late Myocardial 
Remodeling 
YaoLlana Tanq M Ian Phillips, Qiang Zhao, Junbo Ge, University of Florida, College of 
Medicine, Gainesville, FL, Shanghai Institute of Cardiovascular Diseases, Shanghai, 
People’s Republic of China 
Background The remodeling process IS a major cause of heart failure and deaths after 
myocardial infarction (Ml). Marrow stromal cell (MSCs) was shown to enhance angiogen- 
esis and regenerate cardiomyocytes in rat ischemic heart model. This study is designed 
to test the effectiveness of MSCs implantation to reverse myocardial remodeling. 
Methods Autologous MSCs were induced into a zone made ischemic by coronary artery 
ligation 1 week after Ml via intramyocardial(n=lO) or intracoronary (n=lO) implantation. 
Control rats received medium (intramyocardial, n=lO; intracoronaiy, n=lO). Rats with EF 
~70 % 1 week after Ml were included. Scar area index and the scar thickness is mea- 
sured by computer-assistant planimetry as indices of myccardial remodeling 0 weeks 
after implatation. The diameter of myocytes in the p&infarct zcne were also measured. 
Histology study were done by HE and PTAH stain. 
Results Eight weeks after implantations, serial section of transplanted area showing 
regenerated muscle tissue surrounded by host infarction scar in PTAH-stained heart sec- 
tion. lefl ventricular end-diastolic diameter reduced significantly in MSCs group 
(0.706*0.150 mm vs. 0.968+0.094 mm in control group, p<O.Ol). The scar area index 
also reduced in MSCs group (25.5%*5.2% vs. 45.3%+15.2% in control group, PcO.01) 
and the scar thickness increased in MSCs group (1.45iO.32 mm vs. 0.88i0.29mm in 
control group. P-zO.01). Moreover, the myccytes at the peri-infarct zcne of MSCs group 
were significantly larger than that of control group (diameter:0.033+0.011 mm vs. 
0.021+0.009 mm, P<O.Ol). 
Conclusion Our data indicate that MSCs implantation reversed myocardial remodeling 
and improved scar healing by regeneration of muscular tissue after Ml. 
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1025MP-163 Safety of Adjunctive Glycoprotein llblllla Blockade 
During Rescue/Early Percutaneous Coronary 
Intervention Following Full-Dose Fibrinolytic Therapy 
for Acute Myocardial Infarction 
Matthew T. Roe, Robert P. Giugliano, Robed Tuttle, Vie Hasselblad, Sabina Murphy, 
Elliott M. Antman, E. Magnus Ohman. Robert A. Harrington, Christopher 8. Granger, 
Kenneth W. Mahaffey, Christopher P. Cannon, A. Michael Lincoff. C. Michael Gibson, 
Paul W. Armstrong, Frans J. van de Wed, Robert M. Califf, Eric J. Topol, Eugene 
Braunwald, Duke Clinical Research Institute, Durham, NC, TIMI Study Group, Boston, 
MA 
Background: Glycoprotein (GP) llbillla inhibitors improve cutccmes when used during 
primary PCI for ST-elevation myocardial infarctton (STEMI), but the risks and benefits of 
GP Ilb/llla inhibitors dunng rescue/early PCI after full-dose fibrinolytic therapy have not 
been well-characterized. 
Methods: We performed a meta-analysis of data from 11 clinical trials evaluating new 
repedusion regimens for STEMI (ASSENT 1,2, and 3, GUSTO Ill and V, TIMI 108 and 
14. In-TIME-2. SPEED, FASTER, and INTEGRITI). Patients (n = 3,342) treated with full- 
dose fibrinolytic therapy who then underwent early PCI within 24 hours were included. 
The risks of moderate/severe bleeding by the GUSTO scale, intracranial hemorrhage 
(ICH). and 30-day mortality were evaluated stratified by the adjunctive use of GP llbillla 
inhibitors within the first 24 hours. 
Results: Patients treated with GP Ilb/llla inhibitors were younger (mean age 57.3 vs. 
58.3 yrs), heavier (mean weight 84.8 vs. 81.6 kg), less commonly female (18.5% vs. 
20.8%), less commonly had an anterior infarct (40.9% vs. 42.4%), and rncre commonly 
had diabetes (17.0% vs. 14.7%). Unadjusted outcomes are listed in the table. 
GP Ilbl No GP Ilb/ Odds 95% Cl P- 
llla llla Ratio Value 
(n = (n = 2304) 
1038) 
Moderate/Severe Bleeding 17.1 11.6 1.71 1.24. 0.001 
(%) 2.36 
ICH (%) 0.48 0.89 0.75 0.26- 0.586 
2.13 
30.Day Mortality (%) 3.7 4.9 0.78 0.54- 0.214 
1.15 
Conclusions: In this post-hoc, non-randomized analysis, the use of GP Ilb/llla inhibitors 
during rescue/early PCI following full-dose fibrinolytic therapy was associated with a 
higher rate of non-ICH bleeding complications. Prospective, randomized clinical trials are 
therefore needed to delineate the risks and benefits of this treatment strategy. 
12:12 p.m. 
1025MP-164 Prehospital ThrombolyticlAbciximab Therapy in 
Comparison to Facilitated Percutaneous Coronary 
Intervention After Combined Prehospital Thrombolysis 
in Acute Myocardial Infarction 
Holaer Thiele, Lothar Engelmann, Kathleen Elsner, Wulf-Hinrich Starch, Kazem Rahimi, 
Michael Hartmann, Dietrich Pfeiffer, Enno Boudriot, Mathias Kappl, Gerhard Schuler, 
University of Leipzig - Heart Center, Leipzig, Germany 
Background: Prognosis in acute myocardial infarction (AMI) is mainly determined by 
early repelfusion and restoration of a normal flow in the infarct related artery. However, 
reperfusion therapy for AMI with thrombolysis has been shown to achieve a 50% TIMI-3- 
flow only. Early trials combining thrombolysis and PTCA have failed to show a mortality 
benefit mainly due to encountered bleeding complications. Since the reduced fibrinolytic 
therapy in combination with a platelet glycoprotein llblllla inhibitor (COMBO) has recently 
shown to reduce the rate of AMI related complications, ‘“facilitated” PCI needs new eval- 
uation. 
Methods: Since 12/2000 120 patients with an AMI were randomized in Leipzig, Ger- 
many within 6 hours after symptom onset to either a prehospital COMBO (half dose 
Reteplase + abciximab) with in-hospital conservative therapy (r&8) or a prehospital initi- 
ated COMBO therapy with immediate in-hospital “facilitated’ PCl+stent (n=62). Primary 
endpoints were ST-segment resolution at 90 min., infarct size expressed as area under 
the curve of CK-release and as delayed enhancement MRI. The secondary endpoint was 
a composite of mortality, reAMI, major bleeding and stroke. 
Results: Mean time from symptom onset to arrival of the emergency physlcian was 107+ 
81 min. in COMBO only in comparison to 105+ 127 min. in the facilitated PCI-group 
(p=n.s.). In the facilitated PC&group TIMI-3-flow before intervention was 65% and after 
98%, respectively. 90-min ST-segment resolution was mere complete in the facilitated 
PCI group (772 56% vs. 58+ 47%. p=O.O4). Infarct size measured by CK-release was 
900* 817 in the COMBO only versus 847t 482 pmol/l/h in the facilitated PCI-group 
(~~0.07) and 1 I+ 8% versus 7+ 8% in the delayed enhancement MRI (p=O.16). The sec- 
ondary combined endpoint was similar in both groups without an excess in bleeding com- 
plicatlons in the facilitated group. (14% vs. 13%, p=n.s.). 
Conclusion: The prehospital combined thrombolytic therapy with abciximab is feasible 
and these results show that “facilitated” PCl+stent results in a an improved tissue perfu- 
sion as shown by the ST-segment resolution, which leads to a trend of smaller infarcts 
without excess in encountered complications. 
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1025MP-165 A Prospective Multicenter International Randomized 
Trial Comparing Infarct Artery Stenting Alone With 
Infarct Artery Stenting Plus Abcixlmab in Acute 
Myocardial Infarction: Principal Report of the 
Abciximab andsarbostent Evaluation (ACE) Trial 
David Antoniucci. Alfred0 Rodriguez, Albrecht Hempel, Angela Migliorini, Guide Parodi, 
Antonio L. Bartorelli, Antonio Colombo, Giovanni M. Santoro, Guia Moschi. Renato 
Valenti, Leonardo Bolognese. Maurizio Trapani, Cesar F. Vigo, Careggi Hospital, 
Florence, Italy, Otamendi Hospital, Buenos Aires, Argentina 
Background: Previous randomized studies comparing stent plus abclximab with stent 
alone in pts with acute myocardial infarction (AMI) have produced conflicting results 
about the benefit of abciximab as adjunctive treatment to infarct artery stenting. How- 
ever, these studies enrolled mainly low-risk patients, or were done with first generation 
stents. 
Methods: To determine the impact of abciximab therapy as adjunct to infarct artery 
stenting in AMI, 400 pts. without any restriction based on age or clinical status on presen- 
tation, were randomized at 4 sites to primary stenting alone (n =200) or stenting plus 
abciximab (n=200). The stent used was the Carbostant (Sorin. Italy). There were no 
angiographic exclusion criteria except for a reference Infarct artery diameter < 2.5 mm. 
The primary endpoint of the study was the 1 -month composite incidence of death, reinf- 
arction. repeat target vessel revascularization (TVR), and stroke (MACCE). 
Results: Mean age 63.7 f 12.7; ) 70 yrs 36%; female 23%; diabetes 17%; anterior AMI 
43%; cardiogenic shock 9%; not-low-risk patients (TIMI criteria) 66%; median time from 
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AMI onset to revascularization 3.95 hours; primary fatlure 0.7 %. The primary clinical 
endpoint data appear in the table. Multivariate analysis showed abciximab as indspen- 
dently related to l-month outcome (HR 0.41; 95% Cl 0.17-0.97, p=O.O41). 
Abciximab Stent Alone p value 
n=200 n=200 
Death 7 (3.5%) a (4%) 0.792 
Reinfarction 1 (0.5%) 9 (4.5%) 0.010 
TVR 1 (0.5%) 3 (1.5%) 0.315 
Stroke 0 1 (0.5%) 0.317 
MACCE 9 (4.5%) 21 (10.5%) 0.023 
1025MP-166 
12:36 p.m. 
Improved Clinical Outcomes With Abciximab Therapy in 
Acute Myocardlal Infarction: A Systematic Overview of 
Randomized Clinical Trials 
David E. Kandzari, Vie Hasselblad, James E. Tcheng, Gregg W. Stone, Robert M. Califf, 
Sorin J. Brewer. Gilles Montalescot. Franz-Josef Neumann, Adnan Kastrati, Robert A. 
Harrington. Duke Clintcal Research Institute, Durham, NC 
Background- Investigations examining glycoprotein (GP) Ilb/llla inhibition in primary 
percutaneous coronary intervention (PCI) have suggested the efficacy of abciximab in 
improvtng early clinical and angiographic outcomes, yet sample size limitations and vari- 
ability in trial design precluded the results from any individual study from being definitive. 
Methods-We identified 4 randomized trials of primary PCI for acute ST-elevation myo- 
cardial infarction (Ml) (ADMIRAL, CADILLAC, ISAR-2, RAPPORT) with the followtng 
characteristics: comparison of GP llbillla antagonists with placebo or control therapy; 
enrollment of ~200 pts; and description of a 30.day clinical endpoint that included the 
variables of death (D), repeat Ml (reMI), and urgent target vessel revascularization 
(TVR). The primary efficacy endpoint was a composite of D. reMI, or ischemia-driven 
TVR at 30 days. 
Results-Among 3,266 pts with MI, there were no stgnificant differences between patients 
randomized to abciximab (n=l643) or those assigned to placebo or control (n=1623). 
Thirty day clinical events are summarized. 
30-day Clinical Outcome Odds Ratio (95% Cl) 
Death 0.73 (0.46, 1.16) 
ReMl 0.72 (0.39, 1.34) 
Ischemra-dnvenTVR 0.46 (0.30, 0.70) 
Death or reMl 0.72 (0.49, 1.05) 
Death, reMI, or ischemia-driven NR 0.54 (0.40, 0.72) 
Conclusions-In this first systematic overview of clinical trials evaluating early outcomes 
with GP Ilb/llla inhibition in primary PCI, abciximab was associated with significant 
reductions in the 30.day composite endpoint of D, reMI, and ischemic NR and a trend 
toward reductions in 30.day D or reMI. These findings strongly encourage the use of 
intravenous GP llblllla inhibition as adjunctive therapy in primary PCI. 
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1025MP-167 Effect of Abciximab on Myocardial Microcirculation 
After Successful Primary Percutaneous Coronary 
Intervention for Acute ST-Segment Elevation 
Myocardial Infarction 
Stephanie Lehrke, Henning Steen, Ralph Toelg. Uwe K. Wiegand, Evangelos Giannitsis, 
Huoo A. Katus. Medizinische Universitaetsklinik Heidelbero. Heidelbera. Germanv. -. 
Medizinische Universitaet zu Luebeck, Luebeck, Germany 
Background: Reports on the beneficial role of adjunctive therapy with GPllb/llla inhibitors 
in pts. treated successfully with primary percutaneous coronary intervention (PCI) for 
acute ST-segment elevation myocardial infarction (STEMI) are inconsistent. We sought 
to determine whether and in which subgroups of these pts abciximab improves microvas- 
cular perfusion. 
Methods: We included 145 pts with acute STEMI in whom epicardial perfusion (TIMI 
grade 3 flow, resrdual stenosis ~30%) was restored successfully with primary PCI. 57/ 
145 pts (39%) received the GPllb/llfa inhibitor abciximab. Serum concentrations of car- 
diac troponin T (cTnT) were measured lust prior to reperfusion (TO) and 60 minutes 
thereafter (T60). The TGOiTO ratio was used to estimate tissue-level perfusion, a high 
T60ITO ratio suggesttng a good mtcrovascular perfusion.On basis of TOrTGO ratio, pts 
were divided into quartiles with median T60ITO ratios of 2.03, 6.66,24.61 and 134.5 
respectively. The percentage of pts within the three upper quartiles was compared 
between the two treatment groups. Analysis was done for the entire study population and 
for prespecified subgroups according to age (cut-off 70 yrs.), gender, cTnT status on 
admission (cut-off O.lpglL), time from symptom onset to admission (cut-off 6 h(s), and 
diabetes mellitus 
Results: Both treatment groups compared favourably with respect to basekne clinical 
characteristics. The percentage of pts who obtained T6OiTO ratios within the three upper 
quartiles was significantly higher after administration of abciximab suggesting rmproved 
microvascular perfusion (86% vs. 69%, p=O.O5). Among the prespecified subgroups 
abciximab significantly improved microcirculation in pts with an admission cTnT 20.1 pglL 
(p= 0.04) in males (p=O.O2) and in pts > 70 yrs of age (p=O.Ol).No benficial effect could 
be seen in women, in pts with an admission cTnT <O.Olug/L and in pts < 70 yrs of age. 
Conclusions: Abciximab improves microvascular perfusion in STEMI after successful re- 
establishment of epicardial flow by primary PCI. The treatment benefit seems to be espe- 
cially pronounced in particular subgroups. 
1:00 p.m 
1025MP-168 Reduction of Hospital Mortality in Patients With ST 
Elevation Myocardial Infarction Receiving Glycoprotein 
llb/llla Antagonists: Results of the ACOS Registry 
Anselm K. Gitt, Rudolf Schiele. Steffen Schneider, Harm Wienbergen. Tobias Heer, 
Martin G. Gottwik. Jochen Senaes. ACOS-Studv-Grow. Herzzentrum Ludwiashafen _ _ 
Ludwigshafen, Germany, Klinikum Nuernberg Sued, Nuernberg. Germany 
Background: The beneficial effect of IlbIllla-recpetor antagonists (Ilb/llla) has been 
proven in randomised trials on acute coronary syndromes (ACS). Little data exist on the 
frequency of Ilb/llla use and its influence on outcome of patients with acute ST-elevation 
myocardial infarction (STEMI) in clinical practice. 
Methods: Since June 2000 consecutive patients (pts) with ACS have been enrolled into 
the ACOS-Registry (Acute Coronary Syndrome, 154 hospitals) in Germany. We analy- 
sed the prospective data of STEMI-pts with and without treatment wth Ilb/llla to identify 
the impact of this treatment on hospital outcome. 
Results: Out of 12,61 I consecutive pts with ACS, 5,971 (47%) presented with STEMI. 
2,259 of these pts (37%) were treated with Ilb/llla. Determinants for the use of Ilb/llla in 
STEMI were prehospital delay < 4 hours (OR 1.24, 1.05-l .46) and the performance of 
primary PCI (OR 4.06, 3.12-5.34). Prior STEMI or concomitant diseases, especially dia- 
betes did not influence the decision. STEMI pts treated with Ilb/llla were younger and 
already had received prior PCI more often than pts who were not treated with Ilblllla. 
After adjusting for differences in baseline characteristics and acute reperfusion therapy, 
the use of Ilb/llla in STEMI pts was associated with a 24% reduction of hospital mortality 
(OR 0.76,0.62-0.94). 
Conclusion: The use of Ilb/llla in acute STEMI was associated with an additional 24% 






Stent (relative to PCI) 
Hospital mortality 
STEMI with Ilb/flla STEMI without Ilb/llfa p 
63 66 <O.Ol 
6.2 % 5,3 % co.01 
461 % 42.6 % <O.Ol 
216% 269 % co.01 
60,O % 22,9 % <O.Ol 
81,6% 74,6 % so.01 
6,2 % 11,2% <O.Ol 
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1025MP-169 Outcomes in Patients Requiring Bail-Out Abciximab 
During Primary Intervention in Acute Myocardial 
Infarction: Analysis From the CADILLAC Trial 
Dale T. Ashby, James E. Tcheng, Cindy L. Grines, David A. Cox. Roxana Mehran. Marlin 
P. Fahy, Eulogio Garcia, John J. Griffin, Giulio Guagliumi, Thomas D. Stuckey. Mark 
Turco, Alexandra J. Lansky, Gregg W. Stone, Cardiovascular Research Foundation, 
New York, NY, CADILLAC Investigators 
Eackgrounrt As an adjunct to PCI, glycoprotein Ilb/llla receptor inhibitors may either be 
used prophylactically in all patients or selectively in a bail-out fashion if procedural com- 
plications occur after PCI. The fate of patients requiring bail-out llblllla inhibitors during 
primary PCI for AMI is unknown. 
Methods In the CADILLAC Trial 2,062 patients of any age with AMI within 12 hours of 
symptom onset were randomized to undergo PTCA alone, PTCA plus abciximab (abcx), 
stenting alone or stenting plus abcx. Patients assigned to “no abcx” were permitted to 
cross-over and receive abcx for persistent thrombus, dissection, distal emboli or subopti- 
mal epicardial blood flow refractory to tntra-arterial calcium blockers. 
Results Of 1,030 patients assigned to no abcx, 62 (6.0%) crossed over and were 
administered abcx. 30 day outcomes appear in the Table. 
Conclusiolr Patients not administered up-front llblllla inhibitors in whom atxx is 
required for procedural complications or a suboptimal result have markedly worse proce- 
dural results, more bleeding and greater rates of major adverse cardiac events than 
patients routinely treated with abcx upfront. These data suggest that the proper way to 
use abcx is prophylactically, and conversely question the utility of abcx rn a bail-out appli- 
cation during AMI intervention. 
